zurück

Secukinumab (new indication: juvenile psoriatic arthritis, patients aged 6 ≥ years)

 

Subject:

  • Active Substance: Secukinumab
  • Name: Cosentyx®
  • Therapeutic area: Juvenile psoriatic arthritis
  • Pharmaceutical company: Novartis Pharma GmbH

 

Time table:

  • Start: 15.07.2022
  • Final decision by G-BA: 05.01.2023

 

Final decision:

  • No additional benefit proved